Soleno Therapeutics (NASDAQ:SLNO) issued its earnings results on Wednesday. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.08), Bloomberg Earnings reports.
Soleno Therapeutics traded up $1.75, reaching $1.75, during trading on Thursday, according to MarketBeat.com. 34,500 shares of the stock were exchanged, compared to its average volume of 48,620. Soleno Therapeutics has a twelve month low of $1.76 and a twelve month high of $1.77.
In other news, major shareholder Larry N. Feinberg bought 50,000 shares of the stock in a transaction that occurred on Tuesday, May 15th. The shares were acquired at an average cost of $1.80 per share, for a total transaction of $90,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 69.75% of the stock is currently owned by insiders.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.